HRP20160387T1 - Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor - Google Patents
Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor Download PDFInfo
- Publication number
- HRP20160387T1 HRP20160387T1 HRP20160387TT HRP20160387T HRP20160387T1 HR P20160387 T1 HRP20160387 T1 HR P20160387T1 HR P20160387T T HRP20160387T T HR P20160387TT HR P20160387 T HRP20160387 T HR P20160387T HR P20160387 T1 HRP20160387 T1 HR P20160387T1
- Authority
- HR
- Croatia
- Prior art keywords
- degrees
- alk
- salt
- compound
- positive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607305P | 2012-03-06 | 2012-03-06 | |
| EP13710258.8A EP2822939B1 (en) | 2012-03-06 | 2013-03-06 | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
| PCT/US2013/029304 WO2013134353A1 (en) | 2012-03-06 | 2013-03-06 | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160387T1 true HRP20160387T1 (hr) | 2016-05-20 |
Family
ID=47892060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160387TT HRP20160387T1 (hr) | 2012-03-06 | 2013-03-06 | Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor |
Country Status (28)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA033124B1 (ru) * | 2012-03-06 | 2019-08-30 | Сефалон, Инк. | Применение конденсированного бициклического 2,4-диаминопиримидинового производного для лечения alk- или fak-опосредованного заболевания или нарушения у субъекта |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| JP6849594B2 (ja) * | 2014-12-23 | 2021-03-24 | セファロン、インク． | 縮合二環式２，４−ジアミノピリミジン誘導体を調整する方法 |
| CA3108236A1 (en) | 2018-08-07 | 2020-02-13 | In3Bio Ltd. | Methods and compositions for inhibition of egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors |
| WO2024178339A2 (en) * | 2023-02-23 | 2024-08-29 | The Regents Of The University Of Michigan | Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2532800C (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| SI2287156T1 (sl) | 2003-08-15 | 2013-09-30 | Novartis Ag | 2,4-di(fenilamino)-pirimidini, uporabni pri zdravljenju neoplastičnih bolezni, vnetnih motenj in motenj imunskega sistema |
| JP4989233B2 (ja) * | 2004-02-14 | 2012-08-01 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| WO2005097765A1 (en) | 2004-03-31 | 2005-10-20 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| WO2007098507A2 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| NZ576425A (en) * | 2006-10-23 | 2012-04-27 | Cephalon Inc | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
| EP2311807B1 (en) * | 2006-12-08 | 2015-11-11 | Novartis AG | Compounds and composition as protein kinase inhibitors |
| JP4782239B2 (ja) * | 2007-04-18 | 2011-09-28 | ファイザー・プロダクツ・インク | 異常細胞増殖治療のためのスルホニルアミド誘導体 |
| HUE028278T2 (en) * | 2009-06-10 | 2016-12-28 | Chugai Pharmaceutical Co Ltd | Tetracyclic compound |
| EA033124B1 (ru) * | 2012-03-06 | 2019-08-30 | Сефалон, Инк. | Применение конденсированного бициклического 2,4-диаминопиримидинового производного для лечения alk- или fak-опосредованного заболевания или нарушения у субъекта |
| KR101446742B1 (ko) * | 2012-08-10 | 2014-10-01 | 한국화학연구원 | Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| JP6849594B2 (ja) * | 2014-12-23 | 2021-03-24 | セファロン、インク． | 縮合二環式２，４−ジアミノピリミジン誘導体を調整する方法 |
-
2013
- 2013-03-06 EA EA201691574A patent/EA033124B1/ru not_active IP Right Cessation
- 2013-03-06 ES ES13710258T patent/ES2570976T3/es active Active
- 2013-03-06 EA EA201491641A patent/EA025859B1/ru not_active IP Right Cessation
- 2013-03-06 MX MX2014010613A patent/MX347772B/es active IP Right Grant
- 2013-03-06 MY MYPI2014002428A patent/MY177290A/en unknown
- 2013-03-06 WO PCT/US2013/029304 patent/WO2013134353A1/en not_active Ceased
- 2013-03-06 AU AU2013229995A patent/AU2013229995B2/en active Active
- 2013-03-06 SG SG11201405371PA patent/SG11201405371PA/en unknown
- 2013-03-06 RS RS20160238A patent/RS54689B1/sr unknown
- 2013-03-06 EP EP13710258.8A patent/EP2822939B1/en active Active
- 2013-03-06 ES ES15202516.9T patent/ES2681487T3/es active Active
- 2013-03-06 CN CN201610591742.5A patent/CN106166155B/zh active Active
- 2013-03-06 EP EP15202516.9A patent/EP3056494B1/en active Active
- 2013-03-06 JP JP2014561069A patent/JP6016953B2/ja not_active Expired - Fee Related
- 2013-03-06 NZ NZ630251A patent/NZ630251A/en unknown
- 2013-03-06 SI SI201330151T patent/SI2822939T1/sl unknown
- 2013-03-06 HU HUE13710258A patent/HUE027976T2/en unknown
- 2013-03-06 SG SG10201507865QA patent/SG10201507865QA/en unknown
- 2013-03-06 UA UAA201410832A patent/UA115052C2/uk unknown
- 2013-03-06 MX MX2017006206A patent/MX372740B/es unknown
- 2013-03-06 CA CA2865420A patent/CA2865420C/en active Active
- 2013-03-06 PL PL13710258T patent/PL2822939T3/pl unknown
- 2013-03-06 HR HRP20160387TT patent/HRP20160387T1/hr unknown
- 2013-03-06 ME MEP-2016-68A patent/ME02460B/me unknown
- 2013-03-06 CN CN201380012764.6A patent/CN104159894B/zh active Active
- 2013-03-06 KR KR1020147027590A patent/KR102068374B1/ko active Active
- 2013-03-06 DK DK13710258.8T patent/DK2822939T3/en active
-
2014
- 2014-08-21 IL IL234239A patent/IL234239A/en active IP Right Grant
- 2014-08-21 ZA ZA2014/06147A patent/ZA201406147B/en unknown
- 2014-09-02 US US14/474,928 patent/US9132128B2/en active Active
- 2014-09-05 CL CL2014002353A patent/CL2014002353A1/es unknown
- 2014-09-05 PH PH12014501979A patent/PH12014501979A1/en unknown
-
2015
- 2015-08-12 US US14/824,750 patent/US9339502B2/en active Active
-
2016
- 2016-05-04 US US15/146,164 patent/US9623026B2/en not_active Expired - Fee Related
- 2016-05-10 SM SM201600134T patent/SMT201600134B/it unknown
- 2016-05-10 CY CY20161100390T patent/CY1117565T1/el unknown
- 2016-09-27 JP JP2016188585A patent/JP2017039741A/ja active Pending
-
2017
- 2017-03-07 US US15/451,960 patent/US10111872B2/en active Active
- 2017-05-18 IL IL252364A patent/IL252364B/en active IP Right Grant
-
2018
- 2018-10-26 US US16/172,368 patent/US10632119B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160387T1 (hr) | Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor | |
| HRP20241590T1 (hr) | Supstituirani heterociklički fuzirani ciklički spoj, postupak njegove pripreme i njegova farmaceutska uporaba | |
| HRP20190831T1 (hr) | Mješavina rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| HRP20180455T1 (hr) | Natrijev (2r, 5s, 13ar) -7, 9-diokso-10- ( (2,4,6-trifluorobenzil) karbamoil) -2, 3, 4, 5, 7, 9, 13, 13a-oktahidro-2, 5-metanopirido [1’,2’ : 4.5]pirazino [2,1-b]oksazepin-8-olat | |
| PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| HRP20210681T1 (hr) | Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida | |
| BR112015023705A8 (pt) | compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia) | |
| ME02757B (me) | Indoli | |
| MX2015011818A (es) | Inhibidores quinazolinicos de formas mutadas activantes del receptor del factor de crecimiento epidermico. | |
| PH12013500265A1 (en) | Pharmaceutically active compounds as axl inhibitors | |
| ME02019B (me) | SPOJ IMIDAZ0[4,5-c]KINOLIN-2-0NA I NJEGOVA UPOTREBA KAO DVOJNOG INHIBITORA PI3 KINAZE I MTOR" | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| MX2013008431A (es) | Antagonista del receptor de mineralocorticoides. | |
| HRP20161522T1 (hr) | Derivati 6.7-dialkoksi kinazolina korisni za liječenje poremećaja povezanih s rakom | |
| JP2015509540A5 (cg-RX-API-DMAC7.html) | ||
| MX2016002795A (es) | Compuestos de triazolona y usos de los mismos. | |
| PH12016500322A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| EA027986B9 (ru) | Соединения триазолона и их применение | |
| GB2488788B (en) | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response | |
| JP2013540778A5 (cg-RX-API-DMAC7.html) | ||
| HRP20200935T1 (hr) | Farmaceutski pripravci i njihova upotreba |